The published Phase 2 obesity trial measured weight change at 24 weeks and again at 48 weeks, reporting dose-dependent mean reductions of up to 17.5% and up to 24.2% respectively
Henry is open to all adults
Despite these encouraging trends, the market has hurdles, including due to the high cost of GLP-1 agonists, which may limit access for specific patient populations
Although Semaglutide GLP-1 is an effective tool for achieving weight loss, if you want to continue to enjoy the results after stopping the medication, you will need to be extra diligent about sticking to healthy habits
Sources Finnerup NB, Sindrup SH, Jensen TS
Peptide Therapy Candidates: Individuals focused on recovery, sleep, lean mass, body composition support , or joint/soft-tissue comfort